Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Translational results from NET-001 and NET-002 trials

#3534

Introduction: The role of immunotherapy (IO) and predictive biomarkers in NENs patients remains unclear.

Aim(s): Here, we report the translational results of NET001 and NET002 (NCT03278405, NCT03278379) trials.

Materials and methods: Advanced WHO G2-3 NENs patients from a gastroenteropancreatic (GEP) source or a bronchial primary and 0-2 prior lines of therapy, were treated with avelumab. NET001 investigated G3 poorly differentiated (PD) neuroendocrine carcinomas (NECs), whereas NET002 investigated G2-3 well differentiated (WD). We performed whole-exome and transcriptome sequencing from pretreatment samples to identify genomic aberrations and to assess tumor gene expression and infer immune infiltration.

Conference:

Presenting Author: Rodriguez Freixinos V

Authors: Rodriguez-Freixinos V, Bruce J, Chan D, Nunez-Rodriguez J, Mackenzie D,

Keywords: neuroendocrine, cell, research, immunotherapy,